

Contents

OTC reshaping gathers momentum	5
<i>Either you eat or you will be eaten</i> (go to now).....	5
<i>Successes and failures in switching</i> (go to now).....	6
<i>High-profile switch candidates run into trouble</i> (go to now).....	8
<i>Attempts to switch oral contraceptives</i> (go to now).....	9
<i>Germany considers interesting switch applications</i> (go to now).....	10
<i>GlaxoSmithKline’s product supply problems</i> (go to now).....	11
<i>Senior executives coming and going</i> (go to now).....	12
<i>Impact of Viehbacher’s departure from Sanofi</i> (go to now).....	13
<i>NBTY recruits from Coca-Cola</i> (go to now).....	13
<i>Pfizer seeking replacement for Sturman</i> (go to now).....	13
<i>Big OTC businesses changing hands</i> (go to now).....	14
<i>The appeal of asset swaps</i> (go to now).....	15
<i>“Important milestone” for Bayer’s OTC strategy</i> (go to now).....	16
<i>Perrigo picks up Omega Pharma</i> (go to now).....	17
<i>Nestlé organises healthcare offering</i> (go to now).....	18
<i>Genomma continues to strike deals</i> (go to now).....	20
<i>Acquirers grabbing sports-nutrition assets</i> (go to now).....	21
<i>Generics companies keen to enter market</i> (go to now).....	21
<i>Thornton & Ross is Stada’s Centre of OTC Excellence</i> (go to now).....	22
<i>Sun Pharmaceutical to acquire Ranbaxy</i> (go to now).....	22
<i>Actavis expanding through acquisitions</i> (go to now).....	23
<i>Private-equity firms snapping up assets</i> (go to now).....	24
<i>Spinning off businesses</i> (go to now).....	27
<i>More consolidation on the way</i> (go to now).....	30
<i>Many companies hungry for acquisitions</i> (go to now).....	31
<i>A real sea change going on right now</i> (go to now).....	33
<i>Consolidation already leading to divestments</i> (go to now).....	34

Contents

Company strategy profiles	36
<i>Bayer remains hungry for OTC acquisitions</i> (go to now)	36
<i>Boehringer pushes into emerging markets</i> (go to now)	49
<i>Church & Dwight steps up acquisitions hunt</i> (go to now)	56
<i>Galenica splits into two ahead of listings</i> (go to now)	62
<i>GSK grabs Novartis but has supply issues</i> (go to now)	66
<i>Johnson & Johnson says "first things first"</i> (go to now)	81
<i>Meda boosts OTC with Rottapharm Madaus</i> (go to now)	90
<i>Merck KGaA wants local OTC critical mass</i> (go to now)	102
<i>Perrigo pushes into Europe with Omega</i> (go to now)	108
<i>Pfizer pursues switches at home and abroad</i> (go to now)	121
<i>Prestige aims to be billion dollar OTC player</i> (go to now)	130
<i>Procter & Gamble pruning brand portfolio</i> (go to now)	143
<i>RB highlights innovation and acquisitions</i> (go to now)	148
<i>Sanofi steps up switch efforts in 2014</i> (go to now)	158
<i>Stada builds on Thornton & Ross acquisition</i> (go to now)	167
<i>Taisho takes action at home and abroad</i> (go to now)	175
<i>Vemedia takes "buy and build" approach</i> (go to now)	182